If you have been reading about Albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Knockout mice also exhibit cerebellar abnormalities and an increase in the number of sympathetic neurons. Certain types of physical exercise have been shown to markedly (threefold) increase BDNF synthesis in the human brain, a phenomenon which is partly responsible for exercise-induced neurogenesis and improvements in cognitive function. Niacin appears to upregulate BDNF and tropomyosin receptor kinase B (TrkB) expression as well. Sleep also influences BDNF expression: short sleep duration in humans has been associated with reduced BDNF levels, and BDNF signaling in turn appears to play a role in the regulation of REM sleep.
In addition, on 6 March 2026, as part of the Ecuador conflict, the United States and Ecuadorian Armed Forces airstriked a single target allegedly belonging to FARC dissidents. The strikes came amid tensions between the United States and Venezuela as Trump steadily increased pressure. Venezuela's Nicolás Maduro repeatedly accused the US of seeking regime change which some third-party sources agree with. Some experts, human rights groups and international bodies have said the killings are illegal under US and international law, and the Colombian and Venezuelan governments have accused the US of extrajudicial murder. In 2025 the Republican-controlled US Senate twice rejected resolutions that would limit Trump's authority to continue military action against Venezuela or airstrikes against alleged drug vessels. On 3 January 2026, Maduro was captured and flown out of the country by US forces.
== Identification == Fossil dinosaur eggshell fragments can be recognized based on three important traits. Their thickness should be roughly uniform, they are usually slightly curved, and their surface is covered in tiny pores. Less frequently, the concave underside of the eggshell fragment will preserve bumps known as mammillae. Sometimes the embryo had absorbed so much of the calcium that the mammillae need a magnifying glass or microscope to be seen. However, there are many kinds of naturally occurring objects which can resemble fossil eggs. These can fool even professional paleontologists.
== Interactions == Lenvatinib inhibits the liver enzyme CYP3A, which also happens to be a metabolic enzyme for the drug. It inhibits the UDP-glucuronosyltransferases UGT1A1 and UGT1A4. Lenvatinib induces CYP3A but not UGT1A1 and UGT1A4. Use of other drugs, especially ones metabolized by the liver enzyme CYP3A, should be monitored in case their plasma concentration changes. In vitro studies have shown that lenvatinib inhibits organic anion transporters 1 and 3 (OAT1 and OAT3). Sunitinib is metabolized in the liver by CYP3A4. It interacts with inducers and inhibitors of CYP3A4 leading to a decrease or increase in the plasma concentration of particular drugs metabolized by the same pathway. It will not change the amount of drug metabolized by the enzyme, because it does not inhibit or induce the enzyme directly. Sunitinib is a substrate of P-glycoprotein and ABCG2 transporters. It acts as an inhibitor for both transporters, especially for ABCG2. Therefore, drugs that are substrates of these carriers will have modified pharmacokinetics. Plasma concentration of sorafenib and paclitaxel may be increased when the drugs are co-administered along with carboplatin. This has no effect on carboplatin. It also increases the AUC of docetaxel, doxorubicin and irinotecan but decreases the AUC of fluorouracil and neomycin, so it is cautionary to administer sorafenib with these drugs as it may alter the plasma concentration. Sorafenib is metabolized by CYP3A4 and UGT1A9. This means that drugs metabolized by these pathways have to be carefully administered.
Sources: en.wikipedia.org
=== Basal chordates === Published information on Pikaia gracilens (a well-known Cambrian fossil) explains evolution of swimming ability in chordates related to myomere shape and function. Specifically, myomeres in this species possessed minimal overlap between successive ones and myosepta dividing them were gently curved. In a biomechanical evaluation, it is presumed that Pikaia were not capable of rapid swimming like in living chordates. Several theories for this idea include lacking fast-twitch muscle fibers, ancestral muscle fiber types more like modern slow-twitch fibers, and less tension on myosepta due to less overlap between successive myomeres. In amphioxus, myomeres run longitudinally along the length of the body in a "V"-shape. As sequential contraction for swimming occurs, force from the myomeres is transmitted via connective tissues to the notochord.
NH4Cl + NaNO2 → N2 + NaCl + 2 H2O Small amounts of the impurities NO and HNO3 are also formed in this reaction. The impurities can be removed by passing the gas through aqueous sulfuric acid containing potassium dichromate. It can also be obtained by the thermal decomposition of ammonium dichromate.
On July 11, 2021, the 2021 Cuban protests began with thousands of Cubans marching in the street as the single largest anti-government protest in Cuba since 1994. On July 14, Grand Master Zamora Fernández and Grand Secretary Carlos A. Pírez Benítez also addressed a letter to the whole of the Cuban people, the government, and all Cuban Freemasons. In this letter, they wrote that dialogue and tolerance were the most important ways to resolve any difference between parties that disagreed with each other. They desired human rights to be universally applied as codified in the Universal Declaration of Human Rights. They said that the events of the protests were foreseeable and entirely preventable; that it was not unordinary for a government to try and contain a protest, but that the Grand Lodge were disheartened by what they viewed as an excessive use of force and violence used by the government against the protestors. They stressed to the government that errors in governing a nation should never be approached with complacency. They wrote that July 14 was a special day of solemn remembrance in the history of Cuban Freemasonry, as it was that day, many years earlier, when the Grand Lodge of Cuba returned to their use of the motto of Liberty, Equality, and Fraternity. They wrote that all people are equal before the law, and that the Grand Lodge of Cuba stood alongside the people of Cuba, and advocated for peace, harmony and justice.
Over time, different civilizations began to create their own herbal medicinal treatments for wounds depending on the trees, shrubs, or any other type of plants located in their environment. These herbal treatments became the oldest form of wound therapy. It is logically assumed that this may not have been a very safe way of treating humans with wounds due to overdosing or choosing the wrong plants to treat a person until the right one was found. Nevertheless, most of the ancient people who were given the duty of healers through the usage of herbs were well accustomed with which plants from their local flora could be used to help the injured. This knowledge was learned and passed down after healers repeatedly used an herbal remedy for a specific wound with the belief that it promoted healing. Numerous ancient herbal remedies and poisons now serve as models for modern medicine. For example, curare, which was an ancient South American arrow poison, was used in the 20th century as the muscle relaxant tubocurarine. Tribesmen conducted various observations on the effects of different plant parts, meaning roots, leaves, etc., on specific wounds. They also observed what seasons, time of day, or moon phase would result in a most active plant. The latter however resulted in a minimal influence in modern medicine as compared to plants' parts or seasons of growth.
== History == The Sinokrot family has worked in food products since 1982, when the company began manufacturing candies, chocolate, and other confectioneries in its first Ramallah factory. Sinokrot has also established the following ventures:
Sources: en.wikipedia.org
=== Physical Response === When exposed to ultrasound, microbubbles oscillate in response to the incoming pressure waves in one of two ways. With lower pressures, higher frequencies, and larger microbubble diameter, microbubbles oscillate, or cavitate, stably. This causes microstreaming near the surrounding vasculature and tissues, inducing shear stresses that can create pores on the endothelial layer. This pore formation enhances endocytosis and permeability. At lower frequencies, higher pressures, and lower microbubble diameter, microbubbles oscillate inertially; they expand and contract violently, ultimately leading to microbubble collapse. This phenomenon can create mechanical stresses and microjets along the vascular wall, which has been shown to disrupt tight cellular junctions as well as induce cellular permeability. Extremely high pressures cause small vessel destruction, but the pressure can be tuned to only create transient pores in vivo. microbubble destruction serves as a desirable method for drug delivery vehicles. The resulting force from destruction can dislodge the therapeutic payload present on the microbubble and simultaneously sensitize the surrounding cells for drug uptake.
=== Alternative medicine === A 2018 Cochrane review on acupuncture and related interventions for the treatment of carpal tunnel syndrome concluded that "Acupuncture and laser acupuncture may have little or no effect in the short term on symptoms of carpal tunnel syndrome (CTS) in comparison with placebo or sham acupuncture." It was also noted that all studies had an unclear or high overall risk of bias and that all evidence was of low or very low quality.
Gish's debating opponents said that he used a rapid-fire approach during a debate, presenting arguments and changing topics quickly. Eugenie Scott, executive director of the National Center for Science Education, dubbed this approach the "Gish gallop", describing it as "where the creationist is allowed to run on for 45 minutes or an hour, spewing forth torrents of error that the evolutionist hasn't a prayer of refuting in the format of a debate". She also criticized Gish for failing to answer objections raised by his opponents. However, Gish said a similar thing about his debate opponents, especially Kenneth Miller. Gish accused Miller of using spread debating, i.e. speaking very fast and bringing up so many points that there was no chance to answer them all. Gish was also criticized for using a standardized presentation during debates. While undertaking research for a debate with Gish, Michael Shermer noted that Gish re-used similar openings, assumptions about his opponent, slides, and even jokes. For example, during the debate, Gish attempted to prove that Shermer was indeed an atheist and therefore immoral, even though Shermer said he was not an atheist and was willing to accept the existence of a divine creator. Massimo Pigliucci, who debated Gish five times, said that Gish ignored evidence contrary to his religious beliefs. Robert Schadewald accused Gish of stonewalling arguments with fabricated data.
Collagenase 3 is an enzyme that in humans is encoded by the MMP13 gene. It is a member of the matrix metalloproteinase (MMP) family. Like most MMPs, it is secreted as an inactive pro-form. MMP-13 has a predicted molecular weight around 54 kDa. It is activated once the pro-domain is cleaved, leaving an active enzyme composed of the catalytic domain and the hemopexin-like domain PDB: 1PEX. Although the actual mechanism has not been described, the hemopexin domain participates in collagen degradation, the catalytic domain alone being particularly inefficient in collagen degradation. During embryonic development, MMP-13 is expressed in the skeleton as required for restructuring the collagen matrix for bone mineralization. In pathological situations it is highly overexpressed; this occurs in human carcinomas, rheumatoid arthritis and osteoarthritis. Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The protein encoded by this gene cleaves type II collagen more efficiently than types I and III. It may be involved in articular cartilage turnover and cartilage pathophysiology associated with osteoarthritis. The gene is part of a cluster of MMP genes which localize to chromosome 11q22.3.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.